WallStSmart

Jfrog Ltd (FROG)vsZepp Health Corp (ZEPP)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Jfrog Ltd generates 105% more annual revenue ($531.84M vs $258.90M). FROG leads profitability with a -13.5% profit margin vs -15.5%. ZEPP earns a higher WallStSmart Score of 41/100 (D).

FROG

Avoid

28

out of 100

Grade: F

Growth: 7.3Profit: 2.0Value: 5.3Quality: 5.3
Piotroski: 3/9Altman Z: 1.44

ZEPP

Hold

41

out of 100

Grade: D

Growth: 4.7Profit: 2.0Value: 6.7Quality: 5.0
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

FROGUndervalued (+9.8%)

Margin of Safety

+9.8%

Fair Value

$57.63

Current Price

$46.44

$11.19 discount

UndervaluedFair: $57.63Overvalued
ZEPPUndervalued (+48.6%)

Margin of Safety

+48.6%

Fair Value

$46.70

Current Price

$17.47

$29.23 discount

UndervaluedFair: $46.70Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

FROG1 strengths · Avg: 8.0/10
Revenue GrowthGrowth
25.2%8/10

Revenue surging 25.2% year-over-year

ZEPP2 strengths · Avg: 10.0/10
Price/BookValuation
1.3x10/10

Reasonable price relative to book value

Revenue GrowthGrowth
43.0%10/10

Revenue surging 43.0% year-over-year

Areas to Watch

FROG4 concerns · Avg: 2.8/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

Return on EquityProfitability
-8.7%2/10

ROE of -8.7% — below average capital efficiency

Altman Z-ScoreHealth
1.442/10

Distress zone — elevated risk

ZEPP4 concerns · Avg: 2.0/10
Market CapQuality
$247.54M3/10

Smaller company, higher risk/reward

Return on EquityProfitability
-17.2%2/10

ROE of -17.2% — below average capital efficiency

EPS GrowthGrowth
-68.1%2/10

Earnings declined 68.1%

Profit MarginProfitability
-15.5%1/10

Currently unprofitable

Comparative Analysis Report

WallStSmart Research

Bull Case : FROG

The strongest argument for FROG centers on Revenue Growth. Revenue growth of 25.2% demonstrates continued momentum.

Bull Case : ZEPP

The strongest argument for ZEPP centers on Price/Book, Revenue Growth. Revenue growth of 43.0% demonstrates continued momentum.

Bear Case : FROG

The primary concerns for FROG are EPS Growth, Piotroski F-Score, Return on Equity.

Bear Case : ZEPP

The primary concerns for ZEPP are Market Cap, Return on Equity, EPS Growth.

Key Dynamics to Monitor

FROG profiles as a growth stock while ZEPP is a hypergrowth play — different risk/reward profiles.

ZEPP carries more volatility with a beta of 1.77 — expect wider price swings.

ZEPP is growing revenue faster at 43.0% — sustainability is the question.

Monitor SOFTWARE - APPLICATION industry trends, competitive dynamics, and regulatory changes.

Bottom Line

ZEPP scores higher overall (41/100 vs 28/100) and 43.0% revenue growth. Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Jfrog Ltd

TECHNOLOGY · SOFTWARE - APPLICATION · USA

JFrog Ltd. provides a DevOps platform for a continuous software release management platform that enables organizations to deliver software updates to any system in the United States. The company is headquartered in Sunnyvale, California.

Zepp Health Corp

TECHNOLOGY · CONSUMER ELECTRONICS · China

Zepp Health Corporation, an activity and biometric data-driven company, develops, manufactures and sells smart wearable technology devices in the People's Republic of China. The company is headquartered in Hefei, the People's Republic of China.

Want to dig deeper into these stocks?